Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,685,605
  • Shares Outstanding, K 90,478
  • Annual Sales, $ 753,200 K
  • Annual Income, $ -263,300 K
  • 60-Month Beta 1.95
  • Price/Sales 2.23
  • Price/Cash Flow N/A
  • Price/Book 1.94
Trade MYGN with:

Options Overview Details

View History
  • Implied Volatility 58.38% ( +0.65%)
  • Historical Volatility 30.94%
  • IV Percentile 60%
  • IV Rank 43.84%
  • IV High 86.06% on 06/20/23
  • IV Low 36.77% on 07/19/23
  • Put/Call Vol Ratio 12.33
  • Today's Volume 120
  • Volume Avg (30-Day) 203
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 2,972
  • Open Int (30-Day) 4,341

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 6
  • High Estimate -0.11
  • Low Estimate -0.28
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.21 +2.31%
on 04/18/24
22.27 -16.34%
on 03/26/24
-3.61 (-16.23%)
since 03/22/24
3-Month
18.21 +2.31%
on 04/18/24
23.75 -21.56%
on 02/28/24
-2.93 (-13.59%)
since 01/24/24
52-Week
13.82 +34.80%
on 10/30/23
24.21 -23.05%
on 06/30/23
-3.24 (-14.81%)
since 04/24/23

Most Recent Stories

More News
Myriad: Q4 Earnings Snapshot

Myriad: Q4 Earnings Snapshot

MYGN : 18.63 (+0.16%)
Myriad: Q3 Earnings Snapshot

Myriad: Q3 Earnings Snapshot

MYGN : 18.63 (+0.16%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

/PRNewswire/ -- USA News Group - According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic...

ONC.TO : 1.47 (+2.80%)
BNTX : 88.09 (-0.45%)
ONCY : 1.0600 (unch)
SGEN : 228.74 (-0.07%)
MYGN : 18.63 (+0.16%)
ILMN : 122.87 (-1.28%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END

ONCY : 1.0600 (unch)
ONC.TO : 1.47 (+2.80%)
SGEN : 228.74 (-0.07%)
MYGN : 18.63 (+0.16%)
ILMN : 122.87 (-1.28%)
BNTX : 88.09 (-0.45%)
BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD

/PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast...

MYGN : 18.63 (+0.16%)
Advancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimism

USA News Group – According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%. The...

ONCY : 1.0600 (unch)
ONC.TO : 1.47 (+2.80%)
SGEN : 228.74 (-0.07%)
MYGN : 18.63 (+0.16%)
ILMN : 122.87 (-1.28%)
BNTX : 88.09 (-0.45%)
Myriad: Q2 Earnings Snapshot

Myriad: Q2 Earnings Snapshot

MYGN : 18.63 (+0.16%)
Stock Index Futures Move Lower as U.S. Debt Ceiling Uncertainty Weighs on Sentiment, PMI Data in Focus

June S&P 500 futures (ESM23) are down -0.14%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.02% this morning as the U.S. debt ceiling impasse kept risk sentiment fragile, while market participants...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
PACW : 7.54 (-2.71%)
NKE : 94.64 (+0.66%)
BAER.Z.IX : 48.710 (+0.72%)
MYGN : 18.63 (+0.16%)
LFCR : 6.33 (-1.86%)
MVST : 0.4498 (-1.32%)
GH : 18.10 (+4.38%)
QTRX : 16.04 (-0.37%)
Exact Sciences Serves Investors Exactly What They Wished For

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The

EXAS : 63.24 (-0.46%)
LH : 207.94 (-0.01%)
MYGN : 18.63 (+0.16%)
DGX : 137.55 (+0.62%)
Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View

Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.

MYGN : 18.63 (+0.16%)
JNJ : 148.53 (-0.69%)
ISRG : 375.01 (-0.55%)
EW : 88.61 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 19.33
2nd Resistance Point 19.08
1st Resistance Point 18.86
Last Price 18.63
1st Support Level 18.39
2nd Support Level 18.14
3rd Support Level 17.92

See More

52-Week High 24.21
Fibonacci 61.8% 20.24
Fibonacci 50% 19.01
Last Price 18.63
Fibonacci 38.2% 17.79
52-Week Low 13.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar